A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 108-121

  Vega, Mario I ^a,b   Baritaki, Stavroula ^a   Huerta Yepez, Sara ^a,c   Martinez Paniagua, Melisa A ^a,b   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

apoptosis; DR5; lymphoma; NK; Rituximab; TRAIL; YY1

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VINCRISTINE;

APOPTOSIS; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA BINDING; HOST CELL; HUMAN; IN VIVO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; T CELL DEPLETION; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; YY1 TRANSCRIPTION FACTOR;

EID: 78651308629     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.531408     Document Type: Article

References (41)

1. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002;29:18-22. (Pubitemid 34594980)
2. Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) 2009;23:610-615.
3. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
4. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
5. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999;26:88-96.
6. Bonavida B, Vega MI. Rituximab-mediated chemosensitiza-tion of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resist Updat 2005;8:27-41.
7. Wallach D, Kang TB, Kovalenko A. The extrinsic cell death pathway and the élan mortel. Cell Death Differ 2008;15:1533-1541.
8. Borgerding A, Hasenkamp J, Engelke M, et al. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol 2010;38:213-221.
9. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 2004;64:7117-7126.
10. Vega MI, Huerta-Yepez S, Jazirehi A, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005;24:8114-8127.
11. Snell V, Clodi K, Zhao S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997;99:618-624.
12. Sancilio S, Grill V, Di Pietro R. A combined approach with rituximab plus anti-TRAIL-R agonistic antibodies for the treatment of haematological malignancies. Curr Pharm Des 2008;14:2085-2099.
13. Daniel D, Yang B, Lawrence DA, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007;110:4037-4046.
14. Vega MI, Huerta-Yepez S, Baritaki S, Martinez-Paniagua MA, Gonzalez-Bonilla CR, Bonavida B. Rituximab sensitizes TRAIL-resistant B-NHL lines to apoptosis by both TRAIL and fully humanized antibodies targeting TRAIL-R1 (mapa-tumumab) and TRAIL-R2 (lexatumumab). Blood 2007;110(Suppl. 1): Abstract 2350.
15. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol 2007;179:5441-5453.
16. Vega MI, Martinez-Paniagua M, Jazirehi AR, et al. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lym-phoma 2008;49:1982-1994.
17. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxy-methylepoxyquinomicin. J Biol Chem 2002;277:24625-24630.
18. Baritaki S, Suzuki E, Umezawa K, et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008;180:6199-6210.
19. Hayakawa Y, Andrews DM, Smyth MJ. Subset analysis of human and mouse mature NK cells. Methods Mol Biol 2010;612:27-38.
20. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximab-mediated cell signaling and chemo/immuno-sensi-tization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009;15:6582-6594.
21. Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009; 183: 4371-4377.
22. Koning AJ, Lum PY, Williams JM, Wright R. DiOC6 staining reveals organelle structure and dynamics in living yeast cells. Cell Motil Cytoskeleton 1993;25:111-128.
23. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-130.
24. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanoui-lides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004;23:3530-3540.
25. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005;175: 2174-2183.
26. Huerta-Yepez S, Vega M, Escoto-Chavez SE, et al. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 2009;20:39-52.
27. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
28. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
29. Tzung SP, Kim KM, Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183-191.
30. MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002;21:6809-6818.
31. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999;274:22532-22538.
32. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-741.
33. Ferla-Bruhl K, Westhoff MA, Karl S, et al. NF-[kappa]B-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene 2006;26:571-582.
34. Katsman A, Umezawa K, Bonavida B. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat 2007;10:1-12.
35. Baader E, Toloczko A, Fuchs U, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 2005;65:7888-7895.
36. Huerta-Yepez S, Rivera-Pazos M, Libra M, et al. Prognostic Significance of Both the Cytoplasmic and Nuclear Over-expression of Yin-Yang 1 (YY1) among Patients with Multiple Myeloma (MIM). Blood (ASH Annual Meeting Abstracts) 2008;112(11):2730.
37. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003;195(2):158-167.
38. Ganten TM, Haas TL, Sykora J, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004;11:S86-S96.
39. Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleo-tides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med 2002;8:725-732.
40. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-1990.
41. Yee L, Fanale M, Dimick K, et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/ TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J Clin Oncol 2007;25(Suppl. 1): Abstract 8078.